Skip to main content

Table 1 Baseline characteristics of participants

From: Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial

 

Treatment Group

P-value

granisetron + sertraline (n = 27)

placebo + sertraline (n = 21)

Mean ± SD

Count (%)

Mean ± SD

Count (%)

Age (years)

35.48 ± 10.97

 

33.44 ± 9.35

 

0.49

Duration of disease (years)

2.33 ± 3.48

 

3.44 ± 5.05

 

0.37

Gender

Female

 

20 (74.1%)

 

13 (61.9%)

0.53

Male

 

7 (25.9%)

 

8 (38.1%)

Education

Illiterate

 

1 (3.7%)

 

0 (0.0%)

0.21

Primary

 

0 (0.0%)

 

1 (4.8%)

Secondary

 

2 (7.4%)

 

1 (4.8%)

High school diploma

 

1 (3.7%)

 

5 (23.8%)

University Education

 

23 (85.2%

 

14 (66.7%)

Marital status

Single

 

16 (59.3%)

 

13 (61.9%)

1

Married

 

11 (40.7%)

 

8 (38.1%)

Employment

Employed

 

15 (55.6%)

 

10 (47.6%)

0.46

Unemployed

 

7 (25.9%)

 

3 (14.3%)

Housewife

 

5 (18.5%)

 

5 (23.8%)

Student

 

0 (0.0%)

 

3 (14.3%)

Previous treatment

Yes

 

12 (44.4%)

 

12 (57.1%)

0.56

No

 

15 (55.6%)

 

9 (42.9%)

Y-BOCS score (week 0)

Total

28.92 ± 7.15

 

27.5 ± 4.95

 

0.44

Obsession

16.62 ± 3.04

 

14.75 ± 3.79

 

0.06

Compulsion

12.48 ± 5.41

 

12.5 ± 3.2

 

0.98

  1. SD: standard deviation; Y-BOCS: Yale-Brown Obsessive-Compulsive Scale